SNHG15: a promising cancer-related long noncoding RNA

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. doi:10.3322/caac.2134927253694
   PubMed Web of Science ®Google Scholar
• Dunham I, Kundaje A, Aldred SF, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74. doi:10.1038/nature1124722955616
   PubMed Web of Science ®Google Scholar
• Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62. doi:10.1038/nrg.2015.1026666209
   PubMed Web of Science ®Google Scholar
• Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–159. doi:10.1038/nrg252119188922
   PubMed Web of Science ®Google Scholar
• Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–641. doi:10.1016/j.cell.2009.02.00619239885
   PubMed Web of Science ®Google Scholar
• Dong D, Mu Z, Zhao C, Sun M. ZFAS1: a novel tumor-related long non-coding RNA. Cancer Cell Int. 2018;18:125. doi:10.1186/s12935-018-0623-y30186041
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Taheri M. Nuclear Enriched Abundant Transcript 1 (NEAT1): a long non-coding RNA with diverse functions in tumorigenesis. Biomed Pharmacother. 2018;111:51–59. doi:10.1016/j.biopha.2018.12.07030576934
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–463. doi:10.1016/j.ccell.2016.03.01027070700
   PubMed Web of Science ®Google Scholar
• Iyer MK, Niknafs YS, Malik R, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015;47(3):199–208. doi:10.1038/ng.319225599403
   PubMed Web of Science ®Google Scholar
• Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016;96(4):1297–1325. doi:10.1152/physrev.00041.201527535639
   PubMed Web of Science ®Google Scholar
• Gutschner T, Richtig G, Haemmerle M, Pichler M. From biomarkers to therapeutic targets-the promises and perils of long non-coding RNAs in cancer. Cancer Metastasis Rev. 2018;37(1):83–105. doi:10.1007/s10555-017-9718-529247341
   PubMed Web of Science ®Google Scholar
• Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–8041. doi:10.1038/sj.onc.120692812970751
   PubMed Web of Science ®Google Scholar
• Hu L, Wu Y, Tan D, et al. Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2015;34:7. doi:10.1186/s13046-015-0123-z25613496
   PubMed Web of Science ®Google Scholar
• Askarian-Amiri ME, Crawford J, French JD, et al. SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. Rna. 2011;17(5):878–891. doi:10.1261/rna.252881121460236
   PubMed Web of Science ®Google Scholar
• Tani H, Torimura M. Identification of short-lived long non-coding RNAs as surrogate indicators for chemical stress response. Biochem Biophys Res Commun. 2013;439(4):547–551. doi:10.1016/j.bbrc.2013.09.00624036268
   PubMed Web of Science ®Google Scholar
• Tani H, Torimura M. Development of cytotoxicity-sensitive human cells using overexpression of long non-coding RNAs. J Biosci Bioeng. 2015;119(5):604–608. doi:10.1016/j.jbiosc.2014.10.01225468426
   PubMed Web of Science ®Google Scholar
• Tani H, Okuda S, Nakamura K, Aoki M and Umemura T. Short-lived long non-coding RNAs as surrogate indicators for chemical exposure and LINC00152 and MALAT1 modulate their neighboring genes. PLoS One. 2017;12(7):e0181628. doi:10.1371/journal.pone.018162828719640
   PubMed Web of Science ®Google Scholar
• Chen SX, Yin JF, Lin BC, et al. Upregulated expression of long noncoding RNA SNHG15 promotes cell proliferation and invasion through regulates MMP2/MMP9 in patients with GC. Tumour Biol. 2016;37(5):6801–6812. doi:10.1007/s13277-015-4404-026662309
   PubMedGoogle Scholar
• Kong Q, Qiu M. Long noncoding RNA SNHG15 promotes human breast cancer proliferation, migration and invasion by sponging miR-211-3p. Biochem Biophys Res Commun. 2018;495(2):1594–1600. doi:10.1016/j.bbrc.2017.12.01329217194
   PubMed Web of Science ®Google Scholar
• Jiang H, Li T, Qu Y, et al. Long non-coding RNA SNHG15 interacts with and stabilizes transcription factor Slug and promotes colon cancer progression. Cancer Lett. 2018;425:78–87. doi:10.1016/j.canlet.2018.03.03829604394
   PubMed Web of Science ®Google Scholar
• Huang L, Lin H, Kang L, et al. Aberrant expression of long noncoding RNA SNHG15 correlates with liver metastasis and poor survival in colorectal cancer. J Cell Physiol. 2019;234(5):7032–7039. doi:10.1002/jcp.2745630317592
   PubMed Web of Science ®Google Scholar
• Ma Y, Xue Y, Liu X, et al. SNHG15 affects the growth of glioma microvascular endothelial cells by negatively regulating miR-153. Oncol Rep. 2017;38(5):3265–3277. doi:10.3892/or.2017.598529048682
   PubMed Web of Science ®Google Scholar
• Zhang JH, Wei HW, Yang HG. Long noncoding RNA SNHG15, a potential prognostic biomarker for hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2016;20(9):1720–1724.27212162
   PubMed Web of Science ®Google Scholar
• Jin B, Jin H, Wu HB, Xu JJ, Li B. Long non-coding RNA SNHG15 promotes CDK14 expression via miR-486 to accelerate non-small cell lung cancer cells progression and metastasis. J Cell Physiol. 2018;233(9):7164–7172. doi:10.1002/jcp.2654329630731
   PubMed Web of Science ®Google Scholar
• Dong YZ, Meng XM, Li GS. Long non-coding RNA SNHG15 indicates poor prognosis of non-small cell lung cancer and promotes cell proliferation and invasion. Eur Rev Med Pharmacol Sci. 2018;22(9):2671–2679. doi:10.26355/eurrev_201805_1496329771418
   PubMed Web of Science ®Google Scholar
• Cui HX, Zhang MY, Liu K, Liu J, Zhang ZL, Fu L. LncRNA SNHG15 promotes proliferation and migration of lung cancer via targeting microRNA-211-3p. Eur Rev Med Pharmacol Sci. 2018;22(20):6838–6844. doi:10.26355/eurrev_201810_1615230402848
   PubMed Web of Science ®Google Scholar
• Liu K, Hou Y, Liu Y, Zheng J. LncRNA SNHG15 contributes to proliferation, invasion and autophagy in osteosarcoma cells by sponging miR-141. J Biomed Sci. 2017;24(1):46. doi:10.1186/s12929-017-0353-928720111
   PubMed Web of Science ®Google Scholar
• Qu C, Dai C, Guo Y, Qin R, Liu J. Long noncoding RNA SNHG15 serves as an oncogene and predicts poor prognosis in epithelial ovarian cancer. Onco Targets Ther. 2019;12:101–111. doi:10.2147/OTT.S18265730588034
   PubMed Web of Science ®Google Scholar
• Ma Z, Huang H, Wang J, et al. Long non-coding RNA SNHG15 inhibits P15 and KLF2 expression to promote pancreatic cancer proliferation through EZH2-mediated H3K27me3. Oncotarget. 2017;8(48):84153–84167. doi:10.18632/oncotarget.2035929137412
   PubMedGoogle Scholar
• Guo XB, Yin HS, Wang JY. Evaluating the diagnostic and prognostic value of long non-coding RNA SNHG15 in pancreatic ductal adenocarcinoma. Eur Rev Med Pharmacol Sci. 2018;22(18):5892–5898. doi:10.26355/eurrev_201809_1591730280769
   PubMed Web of Science ®Google Scholar
• Du Y, Kong C, Zhu Y, et al. Knockdown of SNHG15 suppresses renal cell carcinoma proliferation and EMT by regulating the NF-kappaB signaling pathway. Int J Oncol. 2018;53(1):384–394. doi:10.3892/ijo.2018.439529750422
   PubMed Web of Science ®Google Scholar
• Wu DM, Wang S, Wen X, et al. LncRNA SNHG15 acts as a ceRNA to regulate YAP1-Hippo signaling pathway by sponging miR-200a-3p in papillary thyroid carcinoma. Cell Death Dis. 2018;9(10):947. doi:10.1038/s41419-018-1111-y30237435
   PubMedGoogle Scholar
• Liu Y, Li J, Li F, Li M, Shao Y, Wu L. SNHG15 functions as a tumor suppressor in thyroid cancer. J Cell Biochem. 2019;120(4):6120–6126. doi:10.1002/jcb.2789930623483
   PubMed Web of Science ®Google Scholar
• Liu Y, Li J, Li M, Li F, Shao Y, Wu L. microRNA-510-5p promotes thyroid cancer cell proliferation, migration, and invasion through suppressing SNHG15. J Cell Biochem. 2019. doi:10.1002/jcb.28454
   Google Scholar
• DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–448. doi:10.3322/caac.2141228972651
   PubMed Web of Science ®Google Scholar
• Kwan TT, Bardia A, Spring LM, et al. A digital RNA signature of circulating tumor cells predicting early therapeutic response in localized and metastatic breast cancer. Cancer Discov. 2018;8(10):1286–1299. doi:10.1158/2159-8290.CD-18-043230104333
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193. doi:10.3322/caac.2139528248415
   PubMed Web of Science ®Google Scholar
• Volk RJ, Leal VB, Jacobs LE, et al. From guideline to practice: new shared decision-making tools for colorectal cancer screening from the American Cancer Society. CA Cancer J Clin. 2018;68(4):246–249. doi:10.3322/caac.2145929846954
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Ma W, Xu Z, Wang Y, et al. A positive feedback loop of SLP2 activates MAPK signaling pathway to promote gastric cancer progression. Theranostics. 2018;8(20):5744–5757. doi:10.7150/thno.2889830555578
   PubMed Web of Science ®Google Scholar
• Gambardella V, Cervantes A. Precision medicine in the adjuvant treatment of gastric cancer. Lancet Oncol. 2018;19(5):583–584. doi:10.1016/S1470-2045(18)30131-129567072
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(Suppl 4):iv1–iv62. doi:10.1093/neuonc/nov18926511214
   PubMed Web of Science ®Google Scholar
• Stupp R. Drug development for glioma: are we repeating the same mistakes? Lancet Oncol. 2019;20(1):10–12. doi:10.1016/S1470-2045(18)30827-130522968
   PubMed Web of Science ®Google Scholar
• Dawkins J, Webster RM. The hepatocellular carcinoma market. Nat Rev Drug Discov. 2019;18(1):13–14. doi:10.1038/nrd.2018.14630168534
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–232. doi:10.1038/s41590-018-0044-z29379119
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-229307467
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19. doi:10.1007/978-3-319-24223-1_126667336
   PubMed Web of Science ®Google Scholar
• Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029–3035. doi:10.1200/JCO.2014.59.489526304877
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296. doi:10.3322/caac.2145629809280
   PubMed Web of Science ®Google Scholar
• Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer. Clin Chim Acta. 2013;415:341–345. doi:10.1016/j.cca.2012.10.05823165217
   PubMed Web of Science ®Google Scholar
• Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63(5):318–348. doi:10.3322/caac.2119023856911
   PubMed Web of Science ®Google Scholar
• Kleeff J, Michl P. Targeted therapy of pancreatic cancer: biomarkers are needed. Lancet Oncol. 2017;18(4):421–422. doi:10.1016/S1470-2045(17)30087-628259609
   PubMed Web of Science ®Google Scholar
• Zhu L, Staley C, Kooby D, El-Rays B, Mao H, Yang L. Current status of biomarker and targeted nanoparticle development: the precision oncology approach for pancreatic cancer therapy. Cancer Lett. 2017;388:139–148. doi:10.1016/j.canlet.2016.11.03027916607
   PubMed Web of Science ®Google Scholar
• Ray K. Pancreatic cancer: biomarkers for the early detection of PDAC. Nat Rev Gastroenterol Hepatol. 2017;14(9):504–505. doi:10.1038/nrgastro.2017.111
   PubMed Web of Science ®Google Scholar
• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–524. doi:10.3322/caac.2141128961310
   PubMed Web of Science ®Google Scholar